The strength of ASTCT comes from members like you — professionals who bring fresh perspectives, share their expertise and help move our field forward. Submit interest to serve on an ASTCT Committee or lead a Special Interest Group (SIG) by Nov. 13. ow.ly/LftC50ZXMe2

Gene therapy is transforming what's possible for patients. Join leading clinicians, researchers and innovators at the ASTCT Gene Therapy Summit for timely education, meaningful discussions and insights into the future of care. ow.ly/JTc050ZWQV3

Can TIL therapy become a new treatment option for patients with sarcoma? In this episode of ASTCT Talks, host Daniel Olson, MD, is joined by John Mullinax, MD, and Lauren Banks, MD, PhD, to discuss the emerging role of tumor-infiltrating lymphocyte (TIL) therapy in sarcoma. The conversation explores early clinical results, patient selection, tumor procurement, and the multidisciplinary collaboration needed to bring this promising cellular therapy approach to patients with solid tumors. 🎧 Listen now: ow.ly/7Tqn50ZWQTc

CAR T-cell therapy has already transformed cancer treatment, but what's next? At the ASTCT Clinical Education Conference, Siddhartha Ganguly, MD, FACP, will examine how CAR T-cell therapy is advancing beyond currently approved indications and what these developments could mean for the future of patient care. Join colleagues from across the field and gain valuable clinical insights you can bring back to your practice. 🔗 Register today: ow.ly/3ix850ZWQRe

From tumor heterogeneity and manufacturing challenges to patient access and physician education, the path to bringing cellular therapies to solid tumors requires innovation across the entire care continuum. In this Nucleus Meet the Author spotlight, Roisin E. O'Cearbhaill, MD, discusses the ASTCT-SITC roadmap for accelerating the safe, scalable, and equitable adoption of cellular therapies for patients with solid tumors. Read more: ow.ly/9gcN50ZWQpe

Stay ahead of emerging challenges in toxicity management. Register for the ASTCT Toxicities Conference to hear from leading experts and gain practical knowledge that can support better patient outcomes. ow.ly/Ck5h50ZWQfW

In her latest President’s Message, Margy MacMillan, MD, MSc, FRCPC, reflects on the important role every ASTCT member plays in advancing transplantation and cellular therapy. From advocacy efforts on Capitol Hill to guideline development, education, mentorship, and research, she highlights how our collective expertise helps improve patient care and shape the future of the field. Read more: ow.ly/ESmx50ZWQaR

Join colleagues for breakthrough science, expert-led education, meaningful networking and the latest advances in transplantation and cellular therapy at the upcoming Tandem Meetings. Register by Nov. 20 to secure the lowest rate: ow.ly/LrwC50ZWQ7V

Meet Frederick Locke, MD, chair of ASTCT’s Committee on Cellular Therapy and a leader in the development of CAR T-cell therapy. In this Q&A, Dr. Locke reflects on the experiences that shaped his career, lessons learned as a physician-scientist, the role of ASTCT in advancing the field, and his vision for the future of cellular therapy. Watch the Video: ow.ly/vmSF50ZV54E

Want to attend the Tandem Meetings 2027? Travel grants are now available to help support attendance and participation. Apply today and take advantage of this opportunity to join the global transplantation and cellular therapy community. Apply here: ow.ly/sN0450ZWQ6C

Webinar: Transplanting Older Patients with TP53-Mutated Disease There's still time to register. Join ASTCT on Oct. 15 for an expert-led webinar exploring transplant considerations and emerging data for older patients with TP53-mutated disease. ow.ly/c7pQ50ZWQ1Y

Older patients with TP53-mutated disease present unique challenges and considerations. Join ASTCT on Oct. 15 for an expert discussion on transplant decision-making, evolving treatment approaches and practical strategies for improving patient outcomes. ow.ly/8Wp350ZUpSi

ASTCT's future is shaped by the leaders who step forward today. Nominate yourself or a colleague for the ASTCT Board of Directors and help guide the Society's strategic priorities, advance the field and support the next generation of leaders by Oct. 16. ow.ly/JkKl50ZShvE

How close are we to bringing CAR T-cell therapy directly to patients through in vivo approaches? Explore the latest developments, emerging research and future potential of in vivo CAR T-cell therapy in this ASTCT Learning Center activity. Gain expert insights into one of the field's most exciting areas of innovation and what it could mean for the future of cellular therapy. Thank you to Johnson & Johnson and Legend Biotech for their generous support of this webinar series. 🔗 Learn more: ow.ly/yEFc50ZUkCm

Know someone who would make a great ASTCT leader? Board nominations are open, and we encourage members to help shape the future of the Society by nominating themselves or a deserving colleague by Oct. 16. ow.ly/EqgU50ZShvH

Choosing a conditioning approach means weighing more than intensity alone. How do available RTC approaches compare? What trade-offs should factor into regimen selection? And how can patient- and disease-specific characteristics help guide your decision? Analyze the evidence and strengthen your approach to individualized regimen selection, earning free CE credit along the way: ow.ly/lY7E50ZUq1o

Final call. Abstract submissions for Tandem Meetings 2027 close tomorrow, Oct. 9. Share your research, connect with colleagues and contribute to the science advancing our field. Submit Now: ow.ly/mXCC50ZV56Q

Meet Frederick Locke, MD, chair of ASTCT’s Committee on Cellular Therapy and a leader in the development of CAR T-cell therapy. In this Q&A, Dr. Locke reflects on the experiences that shaped his career, lessons learned as a physician-scientist, the role of ASTCT in advancing the field, and his vision for the future of cellular therapy. Watch the Video: ow.ly/uVjc50ZV54C

What were the biggest advances in ex vivo gene therapy over the past year, and what do they mean for the future of patient care? Join Sung-Yun Pai, MD, of the National Cancer Institute, for Ex Vivo Gene Therapy in 2026: Updates from the Past Year. This session will explore recent clinical data, emerging technologies, evolving treatment approaches and key developments that are shaping the future of gene therapy research and clinical implementation. Register for the Summit: ow.ly/OKlm50ZUpXK

The ASTCT Clinical Education Conference delivers practical, evidence-based education designed for the multidisciplinary care team. Register today to gain actionable insights, learn from experts and stay current on the latest developments in transplantation and cellular therapy. ow.ly/i08V50ZUpUg